The Practical of Interactive Online Learning in the Japanese Language by Using LoiLoNote School Application

This paper introduces a practical example of applying it to language learning based on the author’s experience in the Japanese curriculum at Bina Nusantara University, Indonesia. In 2020, due to the pandemic, it was decided to conduct all classes, and faculty collaboration would be conducted online from Japan. This study proposes a three-year interactive Japanese language learning class, including a face-to- face comparison from February 2021 to February 2023. The approach to classroom practice is only from Japan application presented in this paper. This application, demonstrated in this study, was used in each semester’s classes, and the author found the optimal individual learning method. It should be added that the application was used in grammar and reading classes. The survey results of this study were obtained from two types of surveys, a quantitative survey and a qualitative survey of the students. Students did not find the new learning method as “new” and could use it smoothly. The effectiveness of this application was discussed based on the difference in learning ability and students’ comments after using it. Therefore, this research shows how practical this application is in ensuring interactivity in students’ language learning

Synthetic studies of ancistrocladinium A and B, antileishmanial compounds isolated from a Congolese Ancistrocladus Species

Synthetic studies of ancistrocladinium A and B, antileishmanial compounds isolated from a Congolese Ancistrocladus sp., are described. Buchwald‒Hartwig coupling reaction between the dihydroisoquinoline and the naphthyl triflate failed. The main framework of ancistrocladinium A was constructed by 1,2‒addition of the amine to the naphthoquinone in the presence of celium trichloride as a catalyst. On the other hand, 1,4‒addition of the amine to the naphthoquinone proceeded without catalyst to form the framework of B. These products will be valuable leads for antileishmanial agents

Motivation and Media Used by Tourist When Visiting Sightseeing After Pandemic Covid-19 in Indonesia and Japan

Sightseeing are places that have the attractiveness of an area, and this makes them a place that is visited by many tourists. However, several conditions make sightseeing unknown and rarely visited by tourists, which is the main problem in this study. Through this research, we will find out the motivation of tourists to travel, the media used by tourists to get information, and the attraction of sightseeing that can attract tourists to visit. This research uses survey methods and interviews with tourists to find out the phenomenon directly when tourists visit tourist attractions in Japan and Indonesia. Japan and Indonesia became the object of research because they were affected by the aftermath of the COVID-19 pandemic in their tourist fields. There will also be further analysis of the problems faced by the two countries. Then the results of the data obtained will be analyzed descriptively, and a solution to the problem is sought. Analyzing the results of this study, we found the phenomenon that the way of getting tourist information varies by age. The younger generation uses SNS, while the older generation often uses introductions from acquaintances and maps. It was also found that Japanese people’s motivation for traveling is often to find a place to visit or to have an extraordinary experience. At the same time, Indonesians are often motivated by the desire to refresh themselves

The immunoreceptor adapter protein DAP12 suppresses B lymphocyte–driven adaptive immune responses

Human and mouse B cells lacking functional DAP12 are hyperresponsive, and DAP12 works with MAIR-II (CD300d) to negatively regulate B cell activity

Synthetic studies of ancistrocladinium A and B, antileishmanial compounds isolated from a Congolese Ancistrocladus Species

Synthetic studies of ancistrocladinium A and B, antileishmanial compounds isolated from a Congolese Ancistrocladus sp., are described. Buchwald‒Hartwig coupling reaction between the dihydroisoquinoline and the naphthyl triflate failed. The main framework of ancistrocladinium A was constructed by 1,2‒addition of the amine to the naphthoquinone in the presence of celium trichloride as a catalyst. On the other hand, 1,4‒addition of the amine to the naphthoquinone proceeded without catalyst to form the framework of B. These products will be valuable leads for antileishmanial agents

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo